A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS

Completed · Not applicable

Conditions studied: Amyotrophic Lateral Sclerosis, ALS

In brief

ALS, also known as "Lou Gehrig's" disease, is a neurodegenerative disease which is fatal. Treatment for ALS is limited and currently consists of primary symptom relief or support. In addition, time from diagnosis to death averages 3-5 years. New Biotic, LLC has submitted an Orphan Drug Designation Application for an investigational probiotic and have indicated the need for more study of this orphaned drug in ALS patients.

Key facts

Study ID
NCT03324399
Run by
Avera McKennan Hospital & University Health Center
People needed
5
Starts
2017-06-01
Expected to finish
2019-06-26
Last updated by the study team
2019-07-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.